8-KOther Events

PFIZER INC 8-K Report (Nov 14, 2003)

Filed November 14, 2003For Securities:PFE

Summary

This 8-K filing by Pfizer Inc. (PFE) provides unaudited pro forma condensed combined financial information for the nine months ended September 28, 2003, reflecting the acquisition of Pharmacia Corporation, which closed on April 16, 2003. The report details the combined income statement as if the merger had occurred on January 1, 2003, highlighting the significant financial impact of this major acquisition. Key takeaways include the combined revenues, a substantial in-process research and development (IPR&D) charge of $5.043 billion related to the acquisition, and significant purchase accounting adjustments affecting cost of sales, administrative expenses, and other deductions. The filing aims to provide investors with a clearer picture of the combined entity's financial performance post-merger, while also outlining the basis of presentation and important notes regarding pro forma adjustments and future expectations.

Key Highlights

  • 1The report presents unaudited pro forma condensed combined income statement for the nine months ended September 28, 2003, reflecting the acquisition of Pharmacia.
  • 2The acquisition of Pharmacia was completed on April 16, 2003, and accounted for as a purchase business combination.
  • 3Combined revenues for the nine-month period are reported at $34.728 billion.
  • 4A significant $5.043 billion charge for merger-related in-process research and development (IPR&D) is recognized.
  • 5Pro forma adjustments include eliminations of intercompany transactions, amortization of intangible assets, and incremental purchase accounting impacts on various expense lines.
  • 6The filing notes estimated annual cost savings of about $4.0 billion by 2005, but provides no assurance these will be fully realized.
  • 7The pro forma statements do not reflect certain restructuring and integration charges estimated between $2.5 and $3.0 billion, as they are not expected to have a continuing impact.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide investors with unaudited pro forma condensed combined financial information that reflects the significant acquisition of Pharmacia Corporation by Pfizer Inc. This allows stakeholders to understand the combined company's financial performance as if the merger had occurred at the beginning of the reporting period.

The acquisition of Pharmacia Corporation was accounted for as a purchase business combination by Pfizer under U.S. Generally Accepted Accounting Principles. This means that Pharmacia's assets and liabilities were recorded at their fair values as of the acquisition date (April 16, 2003).

The pro forma statement shows combined revenues of $34.728 billion for the nine months ended September 28, 2003. A notable item is a $5.043 billion charge for merger-related in-process research and development (IPR&D). Additionally, there are significant adjustments related to purchase accounting, including increased amortization and depreciation expenses and the elimination of pre-acquisition intercompany transactions.

The filing mentions that Pfizer expects to realize annual cost savings of approximately $4.0 billion by 2005. However, it also states that there can be no assurance that all or any material part of these cost savings will be achieved. The pro forma statements themselves do not purport to project future operating results.